Abstract Objective: To assess peripheral blood monocyte tumor necrosis factor receptor (TNFR) levels and plasma soluble tumor necrosis factor receptor (sTNFR) concentrations in critically ill patients with sepsis syndrome. Design: Prospective, descriptive cohort study with no interventions. Setting: Surgical intensive care unit of a tertiary-care hospital associated with a university medical school. Patients: Twenty-one patients with a documented source of infection who met currently accepted criteria for sepsis syndrome/septic shock. Main Outcome Measures: Plasma sTNFR p55 and p75 values were quantified by enzyme-linked immunosorbent assay, and monocyte TNFR levels were assessed by fluorescence flow cytometry after the monocytes were stained with biotinylated human recombinant TNF-α and streptavidin-phycoerythrin. Results: Compared with healthy controls, plasma sTNFR p55 and p75 values were significantly higher (P<.01) in both surviving and nonsurviving patients with sepsis; in nonsurviving patients with sepsis, however, only sTNFR p55 values were significantly (P<.05) higher than in surviving patients with sepsis. By contrast, monocytes from the nonsurviving patients with sepsis manifested a significant (P<.01) and sustained (up to 4 days) decrease in cell surface TNFR values compared with either the normal controls or the surviving patients with sepsis. Conclusions: Assessment of monocyte surface TNFR values may provide a rapid prognostic indicator for patients with sepsis who are at increased risk of death.(Arch Surg. 1996;131:434-437) References 1. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia—United States, 1979-1987 . MMWR CDC Surveill Summ . 1990; 39:31-34. 2. Wenzel RP. Anti-endotoxin monclonal antibodies . N Engl J Med . 1992:326: 1151-1152.Crossref 3. Bone RC. The pathogenesis of sepsis . Ann Intern Med . 1991;115:457-469.Crossref 4. Rackow EC, Astiz ME. The pathophysiology and treatment of septic shock . JAMA . 1991;266:548-554.Crossref 5. Ziegler EJ, Fisher CJ, Sprung CI, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin . N Engl J Med . 1991;324:429-436.Crossref 6. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis . JAMA . 1991;266:1097-1102.Crossref 7. Van Zee KJ, Coyle SM, Calvano SE, et al. Influence of IL-1 receptor blockade on the human response to endotoxemia . J Immunol . 1995;154:1499-1507. 8. Marra MN, Thorton MB, Snable JL, Wilde CG, Scott RW. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5 . Crit Care Med . 1994;22:559-565.Crossref 9. Lowry SF, Calvano SE. Soluble cytokine and hormonal mediators of immunity and inflammation . In: Howard RJ, Simmons RJ, eds. Surgical Infectious Diseases . 3rd ed. Norwalk, Conn: Appleton & Lange; 1995:313-326. 10. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive TNF-alpha in vitro and in vivo . Proc Natl Acad Sci U S A . 1992;89:4845-4849.Crossref 11. Marano MA, Fong Y, Moldawer LL, et al. Serum cachectin/TNF in critically ill burn patients correlates with infection and mortality . Surg Gynecol Obstet . 1990; 170:32-38. 12. Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis . Crit Care Med . 1995;23:376-393.Crossref 13. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever . J Infect Dis . 1990;161:79-84.Crossref 14. Meek M, Munster AM, Winchurch RA, Dickerson C. The Baltimore Sepsis Scale: measurement of sepsis in patients with burns using a new scoring system . J Burn Care Rehabil . 1991;12:564-568.Crossref 15. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome . Ann Intern Med . 1993;119: 771-778.Crossref 16. Van der Poll T, Jansen J, van Leenen D, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia . J Infect Dis . 1993;168:955-960.Crossref 17. Ertel W, Scholl FA, Gallati H, Bonaccio M, Schildberg F-W, Trentz O. Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis . Arch Surg . 1994;129:1330-1337.Crossref 18. Rogy MA, Coyle SM, Rock CS, et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients . J Am Coll Surg . 1994;178:132-138. 19. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils . J Exp Med . 1990;172:599-607.Crossref 20. Leeuwenberg JFM, Dentener MA, Buurman WA. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes: role of CD14, LPS binding protein, and bacteridical/permeability-increasing protein . J Immunol . 1994;152:5070-5076. 21. Ferrante A, Martin AJ, Bates EJ, et al. Interaction of Staphylococcus aureus with human neutrophils and the down-regulation of TNF receptors . J Immunol . 1994;152:3998-4004. 22. Leeuwenberg JFM, Jeunhommee TMAA, Buurman WA. Slow release of soluble TNF receptors by monocytes in vitro . J Immunol . 1994;152:4036-4043. 23. Rogy MA, Oldenburn HSA, Calvano SE, et al. The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock . J Clin Immunol . 1994;14:120-133.Crossref 24. Van der Poll T, Calvano SE, Kumar A, et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans . Blood . 1995:86:2754-2759. 25. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz GA, Balk RA. Sepsis syndrome: a valid clinical entity . Crit Care Med . 1989;17:389-393.Crossref 26. Ding AH, Sanchez E, Srimal S, Nathan CF. Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide . J Biol Chem . 1989;264:3924-3929. 27. Imamura K, Spriggs D, Kufe D. Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand . J Immunol . 1987;139:2989-2992. 28. Winzen R, Wallach D, Engelmann H, et al. Selective decrease in cell surface expression and mRNA level of the 55-kda tumor necrosis factor receptor during differentiation of HL-60 cells in macrophage-like but not granulocyte-like cells . J Immunol . 1992;148:3454-3460.
Archives of Surgery – American Medical Association
Published: Apr 1, 1996